Morgan Stanley Aadi Bioscience, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Morgan Stanley holds 464,466 shares of AADI stock, worth $678,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares

464,466

Previous 510,671 9.05%

Holding current value

$678,120

Previous $1.03 Million 5.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.59 - $2.44 $73,465 - $112,740	-46,205 Reduced 9.05%	464,466 $1.09 Million
Q4 2023 Feb 13, 2024	BUY	$1.97 - $5.41 $574,310 - $1.58 Million	291,528 Added 133.03%	510,671 $1.03 Million
Q3 2023 Nov 15, 2023	BUY	$4.84 - $7.13 $587,740 - $865,824	121,434 Added 124.28%	219,143 $1.06 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $546,174 - $683,516	79,850 Added 447.11%	97,709 $668,000
Q1 2023 May 15, 2023	BUY	$6.85 - $13.0 $103,880 - $197,145	15,165 Added 562.92%	17,859 $129,000

Q4 2022 Feb 14, 2023	SELL	$11.99 - $14.5 $75,692 - $91,538	-6,313 Reduced 70.09%	2,694 $34,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $171,042 - $202,179	-14,218 Reduced 61.22%	9,007 $127,000
Q2 2022 Oct 27, 2022	SELL	$11.57 - $17.92 $145,701 - $225,666	-12,593 Reduced 35.16%	23,225 $286,000
Q2 2022 Aug 15, 2022	SELL	$11.57 - $17.92 $145,701 - $225,666	-12,593 Reduced 35.16%	23,225 $286,000
Q1 2022 Oct 27, 2022	BUY	$16.65 - $24.97 $209,673 - $314,447	12,593 Added 54.22%	35,818 $608,000
Q1 2022 May 13, 2022	BUY	$16.65 - $24.97 $551,564 - $827,181	33,127 Added 1231.03%	35,818 $608,000
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $50,232 - $75,452	2,600 Added 2857.14%	2,691 $65,000
Q3 2021 Nov 15, 2021	BUY	$25.52 - $41.85 $2,322 - $3,808	91 New	91 $3,000

Others Institutions Holding AADI

# of Institutions

Shares Held

13.7M

Call Options Held

4.9K

Put Options Held

700

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $30.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account